• 1
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177182.
  • 2
    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737744.
  • 3
    Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 26392648.
  • 4
    Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28( suppl 3): 1319.
  • 5
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61( suppl 2): 3742.
  • 6
    Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26( suppl 12): 6070.
  • 7
    Nagy P, Jenei A, Damjanovich S, Jovin TM, Szöllösi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999; 5: 255271.
  • 8
    Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61( suppl 2): 1421.
  • 9
    Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002; 62: 31513158.
  • 10
    Austin C, De Maziere A, Pisacane P, van Dijk S, Eigenbrot C, Sliwkowski M, Klumperman J, Scheller R. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15: 52685282.
  • 11
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127137.
  • 12
    Vereb G, Nagy P, Park JW, Szöllősi J. Signaling revealed by mapping molecular interactions: implications for ErbB-targeted cancer immunotherapies. Clin Appl Immunol Reviews 2002; 2: 169186.
  • 13
    Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 11651172.
  • 14
    Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117127.
  • 15
    Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443446.
  • 16
    Carraway KL, Price-Schiavi SA, Komatsu M, Jepson S, Perez A, Carraway CA. Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 2001; 6: 323337.
  • 17
    Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005; 65: 473482.
  • 18
    Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3: 15851592.
  • 19
    Greenfield LJJr, Sun F, Neelands TR, Burgard EC, Donnelly JL, MacDonald RL. Expression of functional GABAA receptors in transfected L929 cells isolated by immunomagnetic bead separation. Neuropharmacology 1997; 36: 6373.
  • 20
    Cook EB, Stahl JL, Lowe L, Chen R, Morgan E, Wilson J, Varro R, Chan A, Graziano FM, Barney NP. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods 2001; 254: 109118.
  • 21
    Segal G, Lee W, Arora PD, McKee M, Downey G, McCulloch CA. Involvement of actin filaments and integrins in the binding step in collagen phagocytosis by human fibroblasts. J Cell Sci 2001; 114: 119129.
  • 22
    Arora PD, Silvestri L, Ganss B, Sodek J, McCulloch CA. Mechanism of cyclosporin-induced inhibition of intracellular collagen degradation. J Biol Chem 2001; 276: 1410014109.
  • 23
    Bausch AR, Ziemann F, Boulbitch AA, Jacobson K, Sackmann E. Local measurements of viscoelastic parameters of adherent cell surfaces by magnetic bead microrheometry. Biophys J 1998; 75: 20382049.
  • 24
    Tanimura N, Nagafuku M, Minaki Y, Umeda Y, Hayashi F, Sakakura J, Kato A, Liddicoat DR, Ogata M, Hamaoka T, et al. Dynamic changes in the mobility of LAT in aggregated lipid rafts upon T cell activation. J Cell Biol 2003; 160: 125135.
  • 25
    Kovacs B, Maus MV, Riley JL, Derimanov GS, Koretzky GA, June CH, Finkel TH. Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. Proc Natl Acad Sci USA 2002; 99: 1500615011.
  • 26
    Shah M, Patel K, Fried VA, Sehgal PB. Interactions of STAT3 with caveolin-1 and heat shock protein 90 in plasma membrane raft and cytosolic complexes. Preservation of cytokine signaling during fever. J Biol Chem 2002; 277: 4566245669.
  • 27
    Ko KS, Arora PD, McCulloch CA. Cadherins mediate intercellular mechanical signaling in fibroblasts by activation of stretch-sensitive calcium-permeable channels. J Biol Chem 2001; 276: 3596735977.
  • 28
    Dai Z, Luo X, Xie H, Peng HB. The actin-driven movement and formation of acetylcholine receptor clusters. J Cell Biol 2000; 150: 13211334.
  • 29
    MacGillivray MK, Cruz TF, McCulloch CA. The recruitment of the interleukin-1 (IL-1) receptor-associated kinase (IRAK) into focal adhesion complexes is required for IL-1beta–induced ERK activation. J Biol Chem 2000; 275: 2350923515.
  • 30
    Wiederkehr-Adam M, Ernst P, Muller K, Bieck E, Gombert FO, Ottl J, Graff P, Grossmuller F, Heim MH. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J Biol Chem 2003; 278: 1611716128.
  • 31
    Brock R, Jovin TM. Heterogeneity of signal transduction at the subcellular level: microsphere-based focal EGF receptor activation and stimulation of Shc translocation. J Cell Sci 2001; 114: 24372447.
  • 32
    Brock R, Jovin TM. Quantitative image analysis of cellular protein translocation induced by magnetic microspheres: application to the EGF receptor. Cytometry 2003; 52A: 111.
  • 33
    Verveer PJ, Wouters FS, Reynolds AR, Bastiaens PI. Quantitative imaging of lateral ErbB1 receptor signal propagation in the plasma membrane. Science 2000; 290: 15671570.
  • 34
    Lidke DS, Lidke KA, Rieger B, Jovin TM, Arndt-Jovin DJ. Reaching out for signals: Filopodia sense EGF and respond by directed retrograde transport of activated receptors. J Cell Biol 2005; 170: 619626.
  • 35
    Kempiak SJ, Yip SC, Backer JM, Segall JE. Local signaling by the EGF receptor. J Cell Biol 2003; 162: 781787.
  • 36
    Lidke DS, Nagy P, Heintzmann R, Arndt-Jovin DJ, Post JN, Grecco H, Jares-Erijman EA, Jovin TM. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 2004; 22: 198203.
  • 37
    Vereb G, Matkó J, Vámosi G, Ibrahim SM, Magyar E, Varga S, Szöllősi J, Jenei A, Gáspár RJr, Waldmann TA, et al. Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. Proc Natl Acad Sci USA 2000; 97: 60136018.
  • 38
    Vereb G, Szöllősi J, Damjanovich S, Matkó J. Exploring membrane microdomains and functional protein clustering in live cells with flow and image cytometric methods. In: GeddesCD, LakowiczJR, editors. Reviews in fluorescence. New York: Kluwer Academic/Plenum; 2004. p 99120.
  • 39
    Bagossi P, Horváth G, Vereb G, Szöllősi J, Tőzsér J. Molecular modeling of nearly full-length ErbB2 receptor. Biophys J 2005; 88: 13541363.
  • 40
    Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284: 5465.
  • 41
    Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002; 8: BR521BR526.
  • 42
    Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, Park JW, Jovin TM, Szöllősi J. Lipid rafts and the local density or ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 2002; 115: 42514262.
  • 43
    Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, Carraway CA, Muller WJ, Carraway KL. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol 2005; 203: 4453.